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Abstract
Background: Patients with difficult-to-control asthma consume 50–60% of healthcare costs attributed to asthma
and cost approximately five-times more than patients with mild stable disease. Recent evidence demonstrates that
not all patients with asthma have a typical type 2 (T2)-driven eosinophilic inflammation. These asthmatics have been
called ‘T2-low asthma’ and have a minimal response to corticosteroid therapy. Adjustment of corticosteroid treatment
using sputum eosinophil counts from induced sputum has demonstrated reduced severe exacerbation rates and
optimized corticosteroid dose. However, it has been challenging to move induced sputum into the clinical setting.
There is therefore a need to examine novel algorithms to target appropriate levels of corticosteroid treatment in
difficult asthma, particularly in T2-low asthmatics. This study examines whether a composite non-invasive biomarker
algorithm predicts exacerbation risk in patients with asthma on high-dose inhaled corticosteroids (ICS) (± long-acting
beta agonist) treatment, and evaluates the utility of this composite score to facilitate personalized biomarker-specific
titration of corticosteroid therapy.
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Methods/design: Patients recruited to this pragmatic, multi-centre, single-blinded randomised controlled trial are
randomly allocated into either a biomarker controlled treatment advisory algorithm or usual care group in a ratio
of 4:1. The primary outcome measure is the proportion of patients with any reduction in ICS or oral corticosteroid
dose from baseline to week 48. Secondary outcomes include the rate of protocol-defined severe exacerbations
per patient per year, time to first severe exacerbation from randomisation, dose of inhaled steroid at the end of the study,
cumulative dose of inhaled corticosteroid during the study, proportion of patients on oral corticosteroids at the end of
the study, proportion of patients who decline to progress to oral corticosteroids despite composite biomarker score of 2,
frequency of hospital admission for asthma, change in the 7-item Asthma Control Questionnaire (ACQ-7), Asthma Quality
of Life Questionnaire (AQLQ), forced expiratory volume in 1 s (FEV1), exhaled nitric oxide, blood eosinophil count, and
periostin levels from baseline to week 48. Blood will also be taken for whole blood gene expression; serum, plasma, and
urine will be stored for validation of additional biomarkers.
Discussion: Multi-centre trials present numerous logistical issues that have been addressed to ensure minimal bias and
robustness of study conduct.
Trial registration: ClinicalTrials.gov, NCT02717689. Registered on 16 March 2016.
Keywords: Asthma, Biomarkers, Corticosteroids, Steroid titration, T2-low, Personalized medicine
Background
Asthma affects an estimated 300 million people worldwide
with a population prevalence of approximately 15% in the
UK [1]. The WHO has estimated UK disability adjusted
life-years per 100,000 population for asthma to be greater
than diabetes and breast cancer [2]. In subjects with mild
disease, currently available treatments work well but, in
10–20% of patients with asthma, their condition is difficult
to control [3, 4]. These patients consume 50–60% of the
healthcare costs attributed to asthma [5, 6] and cost ap-
proximately five-times more than patients with mild stable
disease [7]. This high morbidity and disproportionate use
of healthcare resources reflects the considerable un-met
need in this patient group, and their significance for
healthcare providers.
Asthma has been traditionally ‘stratified’ on the basis of
response to ‘step-wise’ incremental treatment, with inhaled
corticosteroid (ICS) therapy forming the cornerstone of
this approach. However, more recently, asthma has been
stratified on the basis of inflammatory phenotype to better
understand disease heterogeneity with a view to developing
biomarkers of therapeutic response and for better targeting
of both new and existing treatments. Using sputum
analysis [8], and more recently whole genome expression
profiling [9], it is clear that even in mild steroid-naive
asthma approximately 50% of patients do not have a
typical type 2 (T2)-driven eosinophilic inflammation, and
are called ‘T2-low asthma’ patients. Perhaps more signifi-
cantly, on the basis of the normal diagnostic criteria for
asthma, this T2-low group is indistinguishable from the
typical ‘T2-high’/eosinophilic group. However, in the
context of therapeutic response, the T2-low patients
have a minimal response to ICS therapy [8, 9]. In severe
disease, the T2-low profile is also prevalent [10, 11],
and in case series of difficult-to-treat patients with
asthma there is substantial evidence that inappropriate
escalation of corticosteroid treatment is frequent, with
significant morbidity due to systemic corticosteroid
exposure [12–14]. In a follow-up analysis of the largest
“real-world” refractory asthma cohort to date in the
British Thoracic Society Difficult Asthma Network in the
UK [15] the most common therapeutic intervention in spe-
cialist centres was the addition of systemic corticosteroid
treatment, with approximately 60% ending up on oral
corticosteroids [16].
Given the evidence that corticosteroid responsiveness
is minimal in the absence of T2-driven inflammation,
there is a need to examine novel algorithms to target
appropriate levels of corticosteroid treatment in difficult
asthma, particularly in patients with low T2 biomarkers.
Patients with high T2 biomarkers are at risk of severe
exacerbations (e.g. baseline fractional exhaled nitric oxide
(FeNO) > 45 ppb predicts frequent exacerbation [17]), and
in this group the key clinical question is whether this is
because of non-adherence to inhaled corticosteroid treat-
ment or whether they have relative corticosteroid-resistant
T2-high asthma and require additional treatment with
biological drugs that target T2 mechanisms (e.g. antibodies
that inhibit interleukin (IL)-5 or IL-13 signalling). Previous
studies in severe asthma have shown that titrating cortico-
steroids against sputum eosinophilia may be efficacious
without increasing cumulative ICS burden [18], but a
sputum monitoring strategy has not been widely taken
up in most secondary or tertiary care settings because
it poses practical implications that make it difficult to
deliver in the clinic [18]. In a number of studies FeNO
monitoring has not shown utility in disease management
[18]. Whereas improved disease outcome was demonstrated
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in mild asthma in pregnancy [19], the value of FeNO in
managing corticosteroid adjustment in more severe disease
is uncertain [15, 18, 20]. Periostin is a secreted matricellular
protein associated with fibrosis whose expression is upregu-
lated by recombinant IL-4 and IL-13 in cultured bronchial
epithelial cells. Measurement of serum periostin has been
shown to be superior at identifying airway eosinophilia
(defined as a composite of bronchial biopsy or sputum
eosinophilia) than sputum alone or FeNO alone [21],
although this was not seen in another study when looking
at sputum eosinophilia alone [22].
We have examined the value of a composite biomarker
strategy using FeNO, blood eosinophils, and serum perios-
tin together to predict exacerbation risk in the placebo
arms of clinical trials with lebrikizumab (anti-IL-13) and
omalizumab (anti-IgE) in patients taking at least 500 μg
fluticasone propionate (FP) and a second asthma controller
[23–25]. These studies were designed to prospectively
collect exacerbation events.
This analysis has demonstrated that each of the three
biomarkers (blood eosinophils, FeNO, serum periostin)
are individually prognostic for exacerbation risk, and
using the three biomarkers in combination through a
‘composite’ scoring system has the potential to refine this
risk prediction (Table 1).
We propose to examine if this composite biomarker
strategy predicts exacerbation risk in patients with asthma
on high-dose ICS (± long-acting beta agonist (LABA))
treatment and to evaluate the utility of this composite
score to facilitate personalised biomarker-specific titration
of corticosteroid therapy in this population. This study will
examine subjects with FeNO< 45 ppb, and the scoring
system will potentially allow identification of a ‘low-risk’,
corticosteroid-unresponsive group in which we can safely
reduce corticosteroid dose. This study will address a
second important question of estimating the proportion
of patients with severe disease who develop typical
(T2)-driven eosinophilic inflammation on progressive
corticosteroid withdrawal.
Our hypothesis is that adjusting corticosteroid therapy
using composite biomarker scores will lead to more
appropriate corticosteroid dosing in severe asthma,
with no increase in exacerbation risk and a reduction
in corticosteroid load compared to standard care. Current
standard care in asthma management guidelines adjusts
corticosteroid treatment based on symptoms, lung function,
and exacerbation history, and we will compare biomarker-
based adjustment to this standard care. This is essential
to confirm that a biomarker-based strategy delivers better
clinical outcomes compared to standard care.
Methods/design
This is a randomised, pragmatic, single-blind (study par-
ticipant), multi-centre, controlled, parallel group trial in
patients with severe asthma (Global Initiative for Asthma
(GINA) steps 4 and 5 classification of asthma severity). It
will compare a composite biomarker-based (blood eosin-
ophils, periostin, or FeNO data) adjustment of cortico-
steroid therapy (biomarker arm, see Tables 2 and 3)
versus adjustments based on asthma symptom control
and lung function (standard symptom-based care). Trial
staff in clinical centres where a biomarker-based treatment
strategy is already used as standard of care (including a
sputum-based strategy) have been instructed that patients
in the symptom-based arm will have therapy adjusted ac-
cording to the clinical trial algorithm to mirror inter-
national treatment guidelines and current clinical practice
in the UK (Tables 4 and 5).
The study is being conducted in 12 centres throughout
England, Scotland, and Northern Ireland in accordance
with the ethical principles that have their origin in the
Declaration of Helsinki, ICH Good Clinical Practice (GCP),
and all applicable regulations. Queens University Belfast is
the principal sponsor for this study (Ref. 15062LH-AS). A
SPIRIT (Standardized Protocol Items: Recommendations
for Interventional Trials) checklist accompanies this proto-
col to verify that all items required to be addressed in a
high-quality trail are included in this protocol (see
Additional file 1). The protocol has been reviewed and
approved by the Office for Research Ethics Northern
Ireland (Ref. 15/NI0158). All individual sites have given
local National Health Service Research and Development
(NHS R&D) approval. The trial has been registered with
ClinicalTrials.gov (NCT02717689).
Table 1 The composite biomarker score is calculated from the
individual biomarker scores, and is the mean of all three scores
rounded to the nearest integer to give the “composite score”
(score of 0, 1 or 2)
Scoring system 0 1 2
Fractional exhaled NO (ppb) < 15 ≥ 15 to < 30 ≥ 30
Blood eosinophil count (N/μL) < 150 ≥ 150 to < 300 ≥ 300
Periostin (ng/ml) < 45 ≥ 45 to < 55 ≥ 55
Table 2 Biomarker-based therapy adjustment
Score Corticosteroid dose
step-wise adjustment
Follow-up
0 Reduce treatment 1 step If score remains 0 on low-dose
corticosteroid – type 2 (T2)-low
severe asthma
1 Maintain current
treatment
Adjust as necessary based on
follow-up scores
2 Increase treatment 1 step If score remains 2 despite maximal
inhaled corticosteroid therapy
necessitating systemic steroid
therapy – T2-high severe asthma
All therapeutic adjustments will be automatically calculated and advised by
the electronic case report form (e-CRF)
Corticosteroid treatment adjustment based on composite biomarker score
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Eligibility criteria
The study is recruiting patients aged 18 to 80 years old
inclusive with severe asthma (GINA steps 4 and 5 clas-
sification) who are currently attending difficult asthma
clinics in specialist centres. All screened non-randomised
patients have the following anonymised details recorded for
CONSORT (Consolidated Standards of Reporting Trials)
reporting: age; gender; ethnicity (if applicable); and the
reason not eligible for trial participation, or if they are
eligible but declined.
Inclusion criteria
Patients must meet the following criteria at screening
for study entry (patients can be rescreened for study entry
up to three times):
1. Age ≥ 18 and ≤ 80 years at screening visit.
2. Able and willing to provide written informed
consent and to comply with the study protocol.
3. Baseline FeNO < 45 ppb at screening.
4. Severe asthma confirmed after assessment by an
asthma specialist. Diagnosed with asthma at least
12 months prior to screening.
5. Current asthma treatment with LABA plus high
doses of inhaled corticosteroids (≥1000 μg FP daily
or equivalent).
6. Patients on an ICS/LABA single inhaler strategy
must be switched to fixed dosing ICS/LABA for
4 weeks prior to screening.
7. Documented history of reversibility of ≥ 12% change
in forced expiratory volume in 1 s (FEV1) within the
past 24 months or during screening period, as
demonstrated by:
– documented airflow obstruction (FEV1/forced
vital capacity (FVC)) < 70%), where FEV1 has
varied by ≥ 12% either spontaneously or in
response to oral corticosteroid (OCS) therapy or
bronchodilators either between or during clinic
visits.
or
– A 20% drop in FEV1 (PC20) to methacholine <
8 mg/mL or a 15% fall in FEV1 (PD15) after
inhaling a cumulative dose of mannitol of ≤
635 mg indicating the presence of airway
hyperresponsiveness. If sites customarily use
histamine to perform tests of airway
responsiveness, this may be used in place of
methacholine.
Exclusion criteria
Patients who meet any of the following criteria are
excluded from study entry:
1. Acute exacerbation requiring oral corticosteroids in
previous 4 weeks before screening.
2. Known severe or clinically significant
immunodeficiency, including, but not limited to,
human immunodeficiency virus (HIV) infection.
Table 4 Symptom-based therapy adjustment (all therapeutic
adjustments will be automatically calculated and advised by the
e-CRF)
Asthma Control (ACQ7) Treatment increased
according to Table 5
ACQ7≥ 1.5 and≥ 1 change from baseline score
OR
severe exacerbation since last visit (past 8 weeks
at baseline randomisation visit)
Increase therapy 1
step
ACQ7 is 1.0 to < 1.5 OR ACQ≥ 1.5 and < 1 change
from baseline score AND
no severe exacerbation since last study
visit (past 8 weeks at baseline randomisation visit)
No change
ACQ7 < 1.0
AND
no severe exacerbation since last study visit
(prior 8 weeks at baseline randomisation visit)
Reduce therapy 1
step
All therapeutic adjustments will be automatically calculated and advised by
the electronic case report form (e-CRF)
ACQ7 7-item Asthma Control Questionnaire
Table 5 Treatment for symptom-based therapy adjustment
(British Thoracic Society guidelines)
Step 1 LABA/low-dose ICS (FP 200 μg or equivalent)
Step 2 LABA/moderate-dose ICS (500 μg FP equivalent)
Step 3 LABA/high-dose ICS (1000 μg FP equivalent)
Step 4 Add Tiotropium
Step 5* Add regular oral steroids (starting dose
5–10 mg per day increasing in 5 mg increments)
* It is recognised that on some occasions patients may require higher doses of
systemic steroids beyond 20 mg prednisolone per day; as with all treatment
steps, particular attention should be paid to adherence with prednisolone, but
if required prednisolone can be increased in further 5-mg increments
The therapeutic adjustments are designed to reflect clinical practice and to be
pragmatic and allow accommodation of currently used combination inhaler
therapies in this population; because of this, ICS will be adjusted in line with the
patient’s prescribed LABA/ICS inhaler device. This will mean in some situations
that LABA is adjusted along with ICS which would reflect usual clinical practice
If patient is on theophylline, leukotriene receptor antagonist, at baseline, these
are not adjusted during study; they are not added during the study
If patient has an Asthma Control Questionnaire (ACQ)7 > 1.5 and corticosteroid
is not increased, tiotropium should be added if no contraindications if patient
is not already on Long-Acting Muscarinic Antagonist (LAMA) therapy or nebu-
lised short-acting anti-muscarinic therapy
If on inhaled steroid monotherapy (nebulised or inhaled) in addition to ICA/LABA
combination therapy, the inhaled steroid monotherapy will be withdrawn initially
If a patient is on oral steroids and reduces to 5 mg per day, they should be
advised to omit their prednisolone on the morning of their next study visit; at
that visit, they should have a morning cortisol checked locally as part of
routine clinical care: if cortisol within normal range of local laboratory
reference value, steroids can be stopped completely if indicated by study
algorithm; if cortisol is present but outside normal reference range of local
laboratory, gradual oral steroid withdrawal in 1 mg increments is carried out; if
cortisol is undetectable, prednisolone is maintained at 5 mg for study duration
FP fluticasone propionate, ICS inhaled corticosteroid, LABA long-acting beta agonist
Hanratty et al. Trials  (2018) 19:5 Page 5 of 13
3. Currently receiving or have historically received
intravenous immunoglobulin for treatment for
immunodeficiency.
4. If recently commenced on a leukotriene receptor
antagonist or theophylline, stable on treatment for
4 weeks prior to screening.
5. Known current malignancy or current evaluation for
a potential malignancy or history of malignancy
within 5 years prior to baseline. With the exception
of basal-cell and squamous-cell carcinomas of the
skin and carcinoma in situ of the cervix uteri that
have been excised and cured.
6. Other clinically significant medical disease or
uncontrolled concomitant disease despite treatment
that is likely, in the opinion of the investigator, to
require a change in therapy or impact the ability to
participate in the study.
7. History of current alcohol, drug, or chemical abuse
or past abuse that would impair or risk the subject’s
full participation in the study, in the opinion of the
investigator.
8. Current self-reported history of smoking (including
electronic inhaled nicotine products) or former
smoker with a smoking history of > 15 pack-years
a. A current smoker is defined as someone who has
smoked one or more cigarettes per day (or
marijuana or pipe or cigar) for ≥ 30 days within the
24 months prior to the screening visit (day –14)
and/or cotinine positive at screening.
b. Any individual who smokes (cigarettes,
marijuana, pipe, or cigar) occasionally, even if for
< 30 days within the 24 months prior to the
screening visit (day –14), must agree to abstain
from all smoking from the time of consent
through to completion of study.
c. A former smoker is defined as someone who has
smoked one or more cigarettes per day (or
marijuana or pipe or cigar) for ≥ 30 days in his or
her lifetime (as long as the 30-day total did not
include the 24 months prior to the screening visit
(day –14)).
d. A pack-year is defined as the average number of
packs per day times the number of years of
smoking.
9. Current use of an immunomodulatory/
immunosuppressive therapy or past use within
3 months or five drug half-lives (whichever is longer)
prior to the screening visit.
10. Use of a biologic therapy including omalizumab at any
time during the 6 months prior to the screening visit.
11. Bronchial thermoplasty within the prior 6 months
of the screening visit.
12. Initiation of or change in allergen immunotherapy
within 3 months prior to the screening visit.
13.Treatment with an investigational agent within
30 days of the screening visit (or five half-lives of the
investigational agent, whichever is longer).
14.Female patients who are pregnant or lactating.
Safety
Safety is assessed by standard adverse event (AE) and
serious adverse event (SAE) reporting and assessment of
clinical laboratory results. In this study population it is
recognised that severe asthma is a variable condition,
prone to worsening and exacerbation. Therefore, for the
purposes of AE reporting, asthma exacerbations are classed
as expected AEs. Patient safety is monitored by document-
ing AEs and the procedures described below for expedited
reporting. All AEs reported or observed during the study
are recorded on the AE page in the electronic case report
form (e-CRF). The Medical Dictionary for Regulatory
Activities (MedDRA) is being used to code all AEs. SAEs
suspected by the investigator to be associated with study
procedures are required to be reported by the investigator
to the Sponsor immediately (i.e. within 24 h after learning
of the event). Given the hypothesis-generating nature of
this study, the Sponsor may choose to conduct an interim
efficacy analysis. The decision to conduct an interim ana-
lysis and the timing of the analysis will be documented in
the statistical analysis plan prior to the conduct of the
interim analysis. The interim analysis will be performed
and interpreted by members of the Trial Management
Group and RASP-UK Executive Management Team. Safety
analyses will include all randomised patients, with patients
allocated to the group associated with the regimen they
actually received.
Power and sample size estimate
The primary efficacy endpoint of this study is the propor-
tion of patients who achieve any reduction in ICS or OCS
dose from baseline to week 48. It is estimated that up to
10% of the patients in the symptom-based algorithm
(control) group will achieve a reduction in ICS or OCS.
Operating characteristics for achieving additional reduc-
tions in the biomarker-based algorithm (active intervention)
group are provided in Table 6, with 200, 300, and 400
subjects with each scenario assuming a patient drop-out
Table 6 Operating characteristics for detecting differences in
the primary endpoint
Total N
(intervention +
control)
Ratio Type
1 error
Proportion of patients achieving
a reduction in ICS or OCS
Power
Control Intervention Difference
400 (320 + 80) 4:1 0.05 10% 26% 16% 83%
300 (240 + 60) 4:1 0.05 10% 29% 19% 83%
200 (160 + 40) 4:1 0.05 10% 34% 24% 83%
Assumes a 20% drop out rate
ICS inhaled corticosteroid, OCS oral corticosteroid
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rate of 20% by week 48 with > 80% power at the two-sided
α = 0.05 significance level with use of the continuity-
corrected chi-squared test for proportions.
Efficacy analyses will be conducted on an intent-to-treat
(ITT) population consisting of all randomised participants
who completed at least one post-baseline efficacy assess-
ment, with patients allocated to the group to which they
were randomised. The number and proportion of patients
who enrol, discontinue, and complete the study will be
tabulated by the Trial Management Group. Reasons for
early termination from the study will be listed and sum-
marised by Trial Management Group. Any eligibility
criteria exceptions and other major protocol deviations
will also be summarized by the Trial Management
Group. A full CONSORT diagram (Fig. 1) will be produced
for the study including patients screened and reason for
screen failure. Demographic and baseline characteristics
(e.g. age, sex, ethnicity, weight, FEV1) will be summarized
for all randomised patients by the Trial Management
Group using descriptive statistics.
Outcome measures and data analysis
The primary outcome measure is the proportion of patients
with any reduction in ICS or OCS dose from baseline to
week 48. For this endpoint, the Cochran–Mantel–Haenszel
chi-square test (or Fisher’s exact) test will be used to
compare the two treatment management arms with add-
itional analysis as required. The descriptive summaries will
include as a minimum counts and proportions. Secondary
outcomes consist of the following:
1. Rate of protocol-defined severe exacerbations* per
patient per year during the 48-week study period
post-randomisation.
Fig. 1 CONSORT diagram displaying flow of patients through the RASP-UK biomarker study
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2. Time in days to first severe exacerbation from
randomisation.
3. Dose of inhaled steroid (μg fluticasone propionate
equivalent) at 48 weeks or at last visit if patient
withdraws early.
4. Cumulative dose of inhaled corticosteroid during the
48-week study period.
5. Proportion of patients on oral corticosteroids at the
end of the 48-week study period.
6. Proportion of patients who decline to progress to
oral corticosteroids despite composite biomarker
score of 2.
7. Frequency of hospital admission for asthma
throughout the 48-week study period.
8. Change in the 7-item Asthma Control Questionnaire
(ACQ-7) from baseline to week 48.
9. Relative change in FEV1 (volume) from baseline to
week 48?
10. Change in exhaled breath nitric oxide (FeNO),
blood eosinophil count and periostin levels from
baseline to week 48?
11. Change in Asthma Quality of Life Questionnaire
(AQLQ) from baseline to week 48.
* A severe asthma exacerbation is defined as new or in-
creased asthma symptoms (including wheeze, cough, dys-
pnoea, or nocturnal awakenings due to these symptoms)
that leads to: 1) at least a doubling of treatment with OCS
for ≥ 3 consecutive days (for subjects on maintenance
OCS); 2) an increase in treatment with OCS to the usual
rescue course of oral steroids (usually ≥ 0.5 mg/kg for sub-
jects not on maintenance OCS for ≥ 3 consecutive days);
and 3) administration of intravenous and/or intramuscular
corticosteroids for asthma hospitalization for asthma.
The rate of protocol-defined severe exacerbations per
patient per year during the 48-week study period post-
randomisation will be estimated by the total number of
protocol-defined exacerbations observed in the group
over the treatment period divided by total patient-weeks
at risk for the group. For each individual patient, weeks
at risk will be computed as the number of days between
the study completion or study discontinuation date and
the date of randomisation (baseline), divided by 7 days.
Poisson regression with over-dispersion will be used in
the analysis to assess the treatment effect on the rate of
protocol-defined asthma exacerbations. The model will
adjust for baseline inhaled steroid dose, asthma control
(ACQ-7 ≤ 1.25 vs > 1.25), and the use of ‘rescue’ steroids
during the past 12 months.
For the continuous endpoints, analysis methods such
as analysis of variance (ANOVA), analysis of covariance
(ANCOVA), or non-parametric tests will be implemented.
The descriptive summaries will include mean, standard
deviation, median, and range. For the categorical variables,
the Cochran–Mantel–Haenszel χ2 (or Fisher’s exact) test
will be used to compare the two treatment management
groups. The descriptive summaries will include counts
and proportions.
Time to first severe exacerbation from randomisation
will be compared between treatment management groups
using a two-sided stratified log-rank test. Results from an
unstratified log-rank test will also be presented. The pro-
portion of subjects reporting severe exacerbations at each
visit will be estimated using Kaplan-Meier methodology.
Estimation of the hazard ratio will be based on a stratified
Cox regression model with the same stratification factor
used in the stratified log-rank test above. The estimates of
the unstratified hazard ratio may also be presented.
The e-CRF has been designed so that all endpoint data
will have to mandatorily be completed prior to concluding
each visit. If an item is not available or is not applicable
(e.g. a pregnancy test in a post-menopausal woman or
male), this will be indicated. Any endpoint-sensitive data
is highlighted to the algorithm keeper in ‘real-time’ and
queried with the clinical centre. In the event of missing
data, analyses of change from baseline endpoints will use
last observation carried forward (LOCF) imputation for
missing values. Missing data for patient-reported outcome
(PRO) assessments (e.g. ACQ-7, AQLQ) will not be
imputed, with the exception of PRO instruments with
specific instructions for handling missing data. Analyses
of the primary endpoint and other asthma exacerbation
endpoints will be based on observed data with no imput-
ation for premature discontinuation from the study.
Biobanking and DNA sampling
At baseline and selected study visits (Fig. 2) blood is taken
for whole blood gene expression. Serum, plasma, and urine
will be stored for validation of additional biomarkers in-
cluding, but not limited to, biomarkers related to asthmatic
airway inflammation, corticosteroid signalling, and putative
inflammatory pathways in severe asthma. There is also an
optional whole blood sample taken for DNA extraction.
This optional DNA sample is collected from patients who
also sign the separate informed consent for a DNA sample
to be taken and stored in the Roche Clinical Repository
(RCR). The RCR is a centrally administered group of
facilities for the long-term storage of human biologic
specimens, including body fluids, solid tissues, and deriva-
tives thereof (e.g. DNA, RNA, proteins, peptides). The pur-
pose of collecting this sample is to determine genetic
factors that may predict response to glucocorticoids, as well
as to understand the relationship between heritable factors
and response to any therapy typically used in the treatment
of uncontrolled asthma, clinical features of uncontrolled
asthma, or safety events. The DNA sample may also be
useful in the discovery of new drug targets or to identify
new biological pathways involved in asthma, developing
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Procedures
Screening 
visit
Baseline 
(Randomisa
tion)
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Visit 6
Close-out visit
Time -2 weeks
(±3 days)
0 weeks
(±3 days)
8 weeks
(±3 days)
16 weeks
(±3 days)
24 weeks
(±3 days)
32 weeks
(±3 days)
40 weeks
(±3 days)
48 weeks
(±3 days)
Informed consent 1
Medical history 1
Vital Signs 
measurements (Temp, 
BP, Pulse, oxygen 
saturation and 
respiration) 1
Weight & Height 
including BMI 1 1
Physical examination 1
Pregnancy test (where 
relevant) 1
ACQ-7 1 1 1 1 1 1 1 1
AQLQ 1 1
Spirometry 1 1 1 1 1 1 1 1
Serum or urinary 
cotinine 1
Serum periostin 
(Central lab) 1 1 1 1 1 1 1 1
Haematology - blood 
eosinophil and 1 1 1 1 1 1 1 1
Procedures
Screening 
visit
Baseline 
(Randomisa
tion)
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Visit 6
Close-out visit
Time -2 weeks
(±3 days)
0 weeks
(±3 days)
8 weeks
(±3 days)
16 weeks
(±3 days)
24 weeks
(±3 days)
32 weeks
(±3 days)
40 weeks
(±3 days)
48 weeks
(±3 days)
neutrophil count
Serum biochemistry and 
theophylline (if on 
theophylline) 1
Serum prednisolone / 
cortisol (if on 
prednisolone) 1
FeNO 1 1 1 1 1 1 1 1
Urine sample 1 1 1 1
Plasma, serum and 
Paxgene sample for 
biobanking 1 1 1
Optional DNA sample 
for biobanking 1
Induced Sputum 1
CRF/e-CRF completion 
including data transfer 
and query resolution 1 1 1 1 1 1 1 1
Exacerbation recording 
/ treatment taken 1 1 1 1 1 1 1 1
Review/reporting of 
subject AEs/SAEs 1 1 1 1 1 1 1 1
Handover to routine 
care (End of Trial) 1
Procedures
Screening 
visit
Baseline 
(Randomisa
tion)
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Visit 6
Close-out visit
Time -2 weeks
(±3 days)
0 weeks
(±3 days)
8 weeks
(±3 days)
16 weeks
(±3 days)
24 weeks
(±3 days)
32 weeks
(±3 days)
40 weeks
(±3 days)
48 weeks
(±3 days)
including Patient 
Question on “Which 
study arm “
Concomitant 
medication check 
including review of 
inhaler technique, 
medication adherence 
and self-management 
plan (at screening) 1
Concomitant 
medication check 
including review of 
inhaler technique and 
medication adherence 
(on study) 1 1 1 1 1 1 1
Specimen Dispatch by 
post/courier 1 1 1 1 1 1 1 1
Instructions/education 
for subject and/or care 
giver (medication 
adjustment) – follow-up 
telephone call (or 
similar) 1 1 1 1 1 1
Fig. 2 Schedule of study procedures. ACQ-7 7-item Asthma Control Questionnaire, AE adverse event, AQLQ Asthma Quality of Life Questionnaire;
BMI body mass index, BP blood pressure, (e-)CRF (electronic) case report form, FeNO fractional exhaled nitric oxide, SAE serious adverse event,
Temp temperature
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biomarker or diagnostic assays and to establish the per-
formance characteristics of these assays, and increasing
knowledge and understanding of inflammatory diseases
and their biology.
An important exploratory objective of this study is to
phenotype exacerbations in both arms. All patients are
asked to contact their clinical centre to arrange clinical
assessment when there is deterioration in their baseline
asthma control for which they plan to increase their
medication according to their self-management plan. This
plan is reviewed at the screening visit (it is recognised this
may be outside the normal working week (Monday to
Friday) during which patients are advised to follow their
management plan and contact their clinical centre on the
next working day or attend out of hours/emergency care
if needed).
Trial conduct
Consent
Informed consent is obtained by the Principal Investigator
(PI), or named delegate, at each site prior to the study par-
ticipant undergoing procedures. A separate consent form is
used for the optional RCR DNA sample (Additional file 2).
Sampling for the RCR is contingent upon the review and
approval of the exploratory research and the RCR portion
of the ICF by each site’s NHS R&D Committee or Ethics
Committee and, if applicable, an appropriate regulatory
body. If a site has not been granted approval for RCR sam-
pling, this section of the protocol will not be applicable at
that site.
Treatment allocation and randomisation
Patients are randomly allocated to either the biomarker-
based arm or symptom-based standard care arm. Treatment
is allocated by a centrally managed computer algorithm
designed by Dendrite Clinical Systems. The ratio of alloca-
tion of patients is 4:1 biomarker-based to symptom-based.
The rationale for using the differential randomisation ratio
is to allow adequate capture of exacerbation events in the
biomarker arm, thus enabling phenotyping of exacerbations
in this group. Randomisation is also stratified by asthma
control (ACQ-7 ≤ 1.5 vs > 1.5) and use of ‘rescue’ steroids
during the past 12 months. Allocation to the treatment
algorithm group is concealed from the participant, and
investigators analysing outcomes will be masked to group
assignment.
Study procedures
Patients will undergo a screening visit (day –14), a baseline
visit (day 0) and six follow-up visits at weeks 8, 16, 24, 32,
and 48 (see Fig. 2 for the schedule of study procedures).
FeNO will be measured using the Aerocrine Vero® [26, 27].
Periostin will be measured using the Elecsys® Periostin assay
developed by Roche Diagnostics (Penzberg, Germany) [28].
Blood eosinophil count will be measured using local
haematology laboratory automated counters reflecting
the pragmatic clinical design.
If a patient attends for an exacerbation visit the proce-
dures outlined in Fig. 3 will be conducted.
Data collection
All clinical trial source documents are held at each site
and all clinical trial visits are documented in the patient’s
clinical records held at the clinical site in line with GCP.
Trial data is being captured by a password -protected
e-CRF hosted by Dendrite Clinical Systems Ltd. (http://
www.e-dendrite.com/). This will provide point-of-care
clinical trial data capture, which assigns a unique identifier
number at the time consent is given. All data are therefore
anonymised and only linked to patient-identifiable data
held securely and locally at the individual NHS clinical
sites. This system ensures that all data points are completed
at data entry and data entry errors are minimised. Data
checking and cleaning and review will be performed prior
to data lock and transfer into the knowledge management
system. The Health Informatics system performs automatic
system back-ups in real time ensuring data cannot be lost
and can always be retrieved (Dendrite Clinical Systems).
The database is monitored by a full audit trail that logs all
data additions, modifications, and deletions for users of the
system.
Procedures for unscheduled  exacerbation visit
(visit within 72 hours of worsening of their clinical
condition for which they have increased their 
medication)
Medical history 1
Vital Signs measurements (Temp, BP, Pulse, oxygen
saturation, and respiration) 1
Spirometry 1
ACQ-7 1
Serum periostin
(Central lab) 1
FeNO 1
Haematology-blood eosinophil and neutrophil count 1
Biochemistry-CRP 1
Spontaneous Sputum processing for differential cell 
count and aliquotting of samples in lysis buffer 1
Urine sample for eicosanoid analysis 
1
Plasma, serum and Paxgene sample for biobanking 1
Concomitant medication check (on study) 1
Specimen Dispatch  by post/courier 1
Instructions/education for subject and/or care giver 1
Fig. 3 Schedule of study procedures: unscheduled exacerbation
visit. ACQ-7 7-item Asthma Control Questionnaire, BP blood pressure,
CRP C-reactive peptide, FeNO fractional exhaled nitric oxide,
Temp temperature
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Trial oversight and monitoring
The chief investigator (LGH) maintains overall responsi-
bility for the conduct of the trial. There is also a Trial
Management Group (comprised of independent clinicians
and patient representatives) and the RASP-UK Executive
Management Team overseeing the setup, conduct,
analysis, and dissemination of the study. Composition,
roles, and responsibilities of these groups can be obtained
by contacting the clinical monitors (Niche Science and
Technology Ltd.). As a representative of the sponsor,
Clinical Research Associates from this company visit the
investigator and study facilities at periodic intervals, in
addition to maintaining necessary telephone and email
correspondence. The monitor maintains current personal
knowledge of the study, including recruitment progress,
through observation, review of study records and source
documentation, and discussion of the conduct of the study
with the investigator and staff. All aspects of the study are
being carefully monitored by the sponsor or its designee
for compliance with applicable government regulation with
respect to current GCP and current standard operating
procedures.
End of trial/early patient withdrawal
The final study visit occurs 48 weeks after randomisation
when all patients have a final assessment. At this visit,
patients have blood samples collected for measurement
of periostin levels and other on-study measurements
(spirometry, ACQ-7, FeNO, PAXgene, and serum sam-
pling). Exacerbations and any additional treatment in the
final study month as well as other concurrent treatment
are recorded. Subjects are also asked which treatment
adjustment arm they were in during the study (biomarker
versus standard care). The study will be considered
complete with the last study assessment for the last patient
participating in the study.
Patients will be withdrawn from the study at the
discretion of the local PI or Chief Investigator (CI) should
anything happen that would adversely affect their partici-
pation or clinical care or require them to have conflicting
treatment, e.g. increased steroid use for inflammatory or
haematological conditions.
Discussion
As a multi-centre trial, there have been numerous logistical
issues that have been addressed to ensure minimal bias and
quality and robustness of study conduct. This study has
been designed to be pragmatic and therefore more reflective
of routine clinical management of patients with severe
asthma, and this will enable the results to be more clinically
relevant and applicable. In developing this protocol, the
RASP-UK Consortium formed a public and patient repre-
sentative group to gain input from patient representatives.
Furthermore, patient representatives have been involved in
ongoing review of participation and site issues.
The pragmatic nature of this study necessitated a
single-blind study design. In a normal clinical setting,
patients who are managed according to their symptoms,
lung function, and exacerbation history (i.e. the standard
care arm in this trial) are advised of any changes to their
corticosteroid treatment on the day of their visit with a
clinician, whereas a biomarker-based strategy introduces
a delay to this clinical decision. To mimic this within the
study, the personnel performing the study visits must
therefore be unblinded regarding treatment group allo-
cation. However, automated algorithms are used for both
arms to produce treatment advice that is intended to re-
move any individual clinician bias. All subjects receive
the same follow-up advisory phone call after the study
visit to advise that the biomarker data are available and
have advised a reduction, increase, or maintenance of
current treatment to ensure subjects remain blinded to
the intervention.
All centres within this study are being monitored by a
Clinical Research Organisation (CRO) specialising in health-
care research delivery. Remote monitoring of data collection
via the eCRF is also possible, permitting timely identification
of incomplete or missing data and standardization of AE/
SAE reporting. Furthermore all study co-ordinators
have been provided with standardized worksheets reinfor-
cing consistency in data collection.
Recruitment to date has been variable across sites for
numerous reasons, i.e. differences in patient demographics
and disease presentation, variability of medical record
keeping and access to historical spirometry assessments,
staffing issues, and patient engagement in other pharmaco-
logical studies. Strategies to promote and increase recruit-
ment have been employed, e.g. weekly emails to all sites
with tips for successful recruitment practice for more
actively recruiting sites, continual CRO engagement with
individual sites to troubleshoot difficult pre-screening
scenarios, and coordinator teleconferences to allow direct
interaction between all coordinators. In doing so, discrep-
ancies regarding reasons for exclusion at the pre-screening
stage have been identified and resolved.
Trial status
Recruitment is currently active at all 12 sites. The
first patient was randomised in January 2016. As of
13 October 2017, 222 patients have been randomised.
Additional files
Additional file 1: Spirit checklist completed as per submission
guidelines. (DOC 122 kb)
Additional file 2: Patient informed consent form template, plus
additional Roche Clinical Repository consent form. (DOCX 101 kb)
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